Filter

Open

Drug Remdesivir Patent, to be Revoked or Not to be Revoked under Public Interest!

14

MAY

2020

On 9 April 2020, the Cancer Patients Aid Association (CPAA) a charitable organisation has written to Central Government for the revocation of recently granted patent of Remdesivir under section 66.

The Remdesivir patent Application No. 201727012821, filed by Gilead Sciences has been granted in India on Feb 18, 2020. The patent states that Remdesvir, is useful for treating “Filoviridae virus infection”. Coincidently, the novel coronavirus also belongs to the same family of Filoviridae virus. Remdesvir has not yet got marketing approval and is undergoing clinical trials on COVID-19. US has also authorised the antiviral drug Remdesvir against Coronavirus.

The CPAA has urged that Remdesvir may be an effective treatment of Coronavirus. Therefore in today’s situation monopoly rights to Gilead Sc. Inc. may be imperative to public interest. Hence, the patent should be revoked under section 66 so that generic version of the drug shall be made available to the people in need.

CPAA has also urged that the granted patent is non-patentable as it lacks novelty, inventive step and also falls within the provisions of section 3d of the Indian patent Act. Lack of novelty and inventive step are the grounds of both post grant opposition and Revocation under section 64. Since one year has not yet completed after the grant of patent therefore CPAA have the option of filing post grant opposition to invalidate the patent. Further, the patentability of a patent under post grant opposition is to be ascertained by the learned Controller or the IPAB and does not have any link with the Central Government.

Now the question arises whether Remdesvir patent may be revoked on the grounds of public interest under section 66.

Section 66 in The Patents Act, 1970 defines the revocation of patent in public interest.

Where the Central Government is of opinion that a patent or the mode in which it is exercised is mischievous to the State or generally prejudicial to the public, it may, after giving the patentee an opportunity to be heard, make a declaration to that effect in the Official Gazette and thereupon the patent shall be deemed to be revoked.

It is to be noted that under public interest Central Government can revoke the patent only when the patented invention is

  • prejudicial to public, or
  • the mode in which invention is worked is mischievous to state.

Central government has exercised his powers twice under section 66 to revoke the patents in India in 1994 and 2012. The first patent revoked under section 66 in 1994 was the Agracetus patent which covers all forms of genetically engineered cotton. It was revoked to preserve the farmer’s right. The second was the revocation of Avesthagen patent which was held prejudicial to public since the patent relates to Traditional knowledge.

The presently granted Remdesvir patent is neither prejudicial to the farmer rights nor is the part of traditional knowledge. Therefore previous judgements cannot be reciprocated to the present case.

Conclusion:

The primary intent of the CPAA is the availability of Remdesvir to the peoples in need at effective cost which is possible if the other manufactures can produce the generic version of Remdesvir. Revocation of patent under section 66 may give birth to the number of controversies and can weaken the Indian patent framework. Other than revocation, the Patent’s Act 1970 has the provision of granting Compulsory licence under special provisions under section 92. Many other countries are also either granting compulsory licences (as in Italy) or amending their laws (Canada) such that granting CL become easier in order to combat COVID 19 situation. However according to the recent reports Gilead has signed voluntary licensing agreements with Cipla Ltd., Ferozsons Laboratories, Hetero Labs Ltd., Jubilant Lifesciences and Mylan to manufacture Remdesivir for distribution in 127 countries such that drugs could be available to the people in need at effective cost.

About the Firm

LexOrbis
Address 709-710 Tolstoy House, 15-17 Tolstoy Marg, New Delhi – 110001
Tel 91-11-2371 6565
Fax 91-11-2371 6556
Email manisha@lexorbis.com
Link www.lexorbis.com

Related Articles

22
APR
2022
The Biological Diversity (Amendment) Bill, 2021
22
APR
2022
The Biological Diversity Act, 2002 was enacted for the conservation of biological diversity, sust...

Read More

25
MAR
2022
Rules on Intellectual Property Matters Notified by High Court of Delhi
25
MAR
2022
In a much-awaited development, the Delhi High Court has notified the “High Court of Delhi Rule...

Read More

07
MAR
2022
Competitor’s Dishonest Intention in Using Similar Word Can Be Injuncted
07
MAR
2022
Recently, the Delhi High Court granted an interim injunction against the defendant until disposal of...

Read More

17
JAN
2022
Supreme Court of India Further Extended the Suspension of Limitation Period/Timelines under General and Special Laws
17
JAN
2022
In view of the spike in new cases of Covid-19, the Hon’ble Supreme Court of India has on...

Read More

08
DEC
2021
Non-speaking Refusal Order Quashed by the Bombay High Court
08
DEC
2021
The Bombay High Court, through an order dated 6th October 2021 in the case of Metso Outotec Corpo...

Read More

29
NOV
2021
Note on the Cryptocurrency and Regulation of Official Digital Currency Bill, 2021
29
NOV
2021
The Cryptocurrency and Regulation of Official Digital Currency Bill, 2021, will be introduc...

Read More

29
NOV
2021
Note on Joint Parliamentary Committee’s Report on the Personal Data Protection Bill, 2019
29
NOV
2021
The Personal Data Protection Bill, 2019 was introduced in the Lower House of the Indian Parliamen...

Read More

11
OCT
2021
Delhi High Court Proposes to Frame Intellectual Property Division (IPD) Rules, 2021
11
OCT
2021
In July, 2021, the Hon’ble Chief Justice of Delhi High Court announced creation of Intellectua...

Read More

04
OCT
2021
Suspension of Limitation Period Due to COVID-19 Withdrawn
04
OCT
2021
On September 23, 2021, the Supreme Court withdrew the suspension of limitation that was in place sin...

Read More

03
AUG
2021
Surrender of a Patent Cause and Effect
03
AUG
2021
Voluntary surrender of a patent and its revocation in a court are two distinct actions through which...

Read More

13
JUL
2021
No Grant of Anti-Suit Injunction if Foreign Proceedings Not Oppressive or Vexatious: Delhi HC
13
JUL
2021
When proceedings are pending in a foreign court against an Indian citizen, such a person can requ...

Read More

16
JUN
2021
Pre-grant Order Appealable: IPAB Precedents Lost?
16
JUN
2021
Judiciously speaking precedential value of every decision of a higher court is high for deciding ...

Read More

26
MAY
2021
Court Recognizes The Seriousness of Medicinal Trademarks
26
MAY
2021
Recently, the Delhi High Court decided the case of Mankind Pharma Limited vs Novakind Bio Sciences P...

Read More

08
APR
2021
Can a Prefix Conceal Infringement?
08
APR
2021
The factor of distinctiveness of a trademark plays a vital role in deciding infringement suits. W...

Read More

07
APR
2021
Intellectual Property Appellate Board Abolished by Way of An Ordinance
07
APR
2021
The Central Government by way of an Ordinance, namely the Tribunals Reforms (Rationalization and Con...

Read More

14
MAR
2021
Claiming Royalty Fee After Delay Cannot Be Sustained
14
MAR
2021
The High Court of Delhi in the case of Ozone Spa Pvt Ltd vs Jyotsna Sanjay Aggarwal & Anr. delibe...

Read More

12
MAR
2021
Extension of Limitation under COVID-19 Comes to an End_Supreme Court Order Dated March 8, 2021
12
MAR
2021
In view of the outbreak of COVID-19 pandemic in March 2020, the Supreme Court of India by an order d...

Read More

07
FEB
2021
‘Knowledge Workers’ and Trade Secret!
07
FEB
2021
Knowledge drives the companies to gain competitive edge over the similarly placed companies in the m...

Read More

21
DEC
2020
Trademark Used Only for Exports Can be Protected
21
DEC
2020
Recently, the Delhi High Court heard a plea for granting an interim injunction in favour of UFO Cont...

Read More

21
DEC
2020
SMEs and Standard Essential Patents (SEPs)
21
DEC
2020
Basics of SEPs A technical standard is a formal document that establishes uniform engineering or te...

Read More

21
OCT
2020
Significant Achievements Witnessed by The IP Office (2014-15 to 2019-20)
21
OCT
2020
National IPR Policy unveiled in the year 2016 has brought out such remarkable changes in the IP. Ad...

Read More

06
AUG
2020
Indian Scenario of Electronic Health Records
06
AUG
2020
Introduction The whole world has been struggling to fight against the COVID-19 (SARS CoV-2) sinc...

Read More

16
JUL
2020
Indian Law on Software Patentability
16
JUL
2020
Software programs have become an indispensable part of the world due to the increased efficiency, ef...

Read More

04
JUN
2020
Artificial Intelligence Systems and IP
04
JUN
2020
The metamorphosis of the community wealth from the physical possession to nonphysical possession lik...

Read More

28
MAY
2020
Issues Related to Patentability of Biotechnological Inventions
28
MAY
2020
Biotechnology is the process of modifying the living organisms in such a way that they become more p...

Read More

  • 1
  • 2